Home > Publications . Search All . Browse All . Country . Browse PSC Pubs . PSC Report Series

PSC In The News

RSS Feed icon

Inglehart says shaky job market for millennials has contributed to their disaffection

Stephenson says homophobia among gay men raises risk of intimate partner violence

Frey says having more immigrants with higher birth rates fills need in the US

More News

Highlights

Savolainen wins Outstanding Contribution Award for study of how employment affects recidivism among past criminal offenders

Giving Blueday at ISR focuses on investing in the next generation of social scientists

Pfeffer and Schoeni cover the economic and social dimensions of wealth inequality in this special issue

PRB Policy Communication Training Program for PhD students in demography, reproductive health, population health

More Highlights

Next Brown Bag

Mon, Jan 23, 2017 at noon:
H. Luke Shaefer

Treatment and Outcomes of First Troponin-Negative Non-ST-Segment Elevation Myocardial Infarction

Archived Abstract of Former PSC Researcher

Corteville, D.C., D.F. Armstrong, D.G. Montgomery, E. Kline-Rogers, Zachary Goldberger, J.B. Froehlich, H.S. Gurm, and K.A. Eagle. 2011. "Treatment and Outcomes of First Troponin-Negative Non-ST-Segment Elevation Myocardial Infarction." American Journal of Cardiology, 107(1): 24-29.

Little is known about non-ST-segment elevation myocardial infarction (MI) in patients with an initial negative troponin finding. The aim of this study was to determine in post hoc analysis of a large regional medical center presenting clinical characteristics, treatment differences, and in-hospital and 6-month outcomes of first troponin-negative MI (FTNMI). In this study, 659 of 1,855 consecutive patients with non-ST-segment elevation MI (35.5%) were classified as having FTNMI. In-hospital cardiac catheterization rates were similar between the 2 groups (70.1% vs 71.5%, p = 0.53) In hospital, patients with FTNMI were less likely to receive statins (48.9% vs 59.9%, p < 0.001). On discharge, patients with FTNMI were less likely to be on clopidogrel (53.1% vs 59.0%, p = 0.019) and statins (67.7% vs 75.2%, p < 0.001). At 6-month follow-up, patients with FTNMI were less likely to be on clopidogrel (43.5% vs 55.2%, p = 0.01) In-hospital recurrent ischemia was 2 times as common in FTNMI (20.1% vs 11.5%, p < 0.001). There were no differences, however, in congestive heart failure, cardiogenic shock, cardiac arrest, stroke, or death in hospital. At 6 months, patients with FTNMI were 2 times as likely to have had recurrent MI (12.0% vs 6.6%, p < 0.001). Combined end points of death at 6 months, MI, stroke, and rehospitalization were higher for FTNMI (47.7% vs 40.9%, p = 0.017); however, this was due to higher rates of recurrent MI. In conclusion, patients with FTNMI received less aggressive pharmacotherapy and were 2 times as likely to have recurrent MI at 6 months. FTNMI is common and represents a clinical entity that should be treated more aggressively. Published by Elsevier Inc. (Am J Cardiol 2011;107:24-29)

DOI:10.1016/j.amjcard.2010.08.040 (Full Text)

Country of focus: United States of America.

Browse | Search : All Pubs | Next